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Abstract
INTRODUCTION—Findings for genetic correlates of late onset Alzheimer’s disease (LOAD) in 
studies that rely solely on clinic visits may differ from those with capacity to follow participants 
unable to attend clinic visits.
METHODS—We evaluated previously-identified LOAD-risk single nucleotide variants in the 
prospective Adult Changes in Thought study, comparing hazard ratios (HRs) estimated using the 
full data set of both in-home and clinic visits (n=1697) to HRs estimated using only data that was 
obtained from clinic visits (n=1308). Models were adjusted for age, sex, principal components to 
account for ancestry, and additional health indicators.
RESULTS—LOAD associations nominally differed for 4 of 21 variants; CR1 and APOE variants 
were significant after Bonferroni correction.
DISCUSSION—Estimates of genetic associations may differ for studies limited to clinic-only 
designs. Home visit capacity should be explored as a possible source of heterogeneity and 
potential bias in genetic studies.
*Corresponding author: Paul K. Crane, MD MPH, Box 359780, 325 Ninth Avenue, Seattle, WA 98104. pcrane@uw.edu. (206) 
744-1831 (phone); (206) 897-4688 (fax). 
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1. Introduction1
Study design is underemphasized in planning or interpretation of many genome-wide 
association studies (GWAS) and sequencing projects [1]. In many settings, issues such as 
sampling, recruitment and data collection strategies are assumed to be of secondary 
importance, although the potential for bias is well-established. Many GWAS analysis 
projects amass participants from cohorts with varying recruitment strategies and 
phenotyping protocols. In resulting manuscripts, these details are often relegated to 
supplementary information or not described at all.
Even subtle differences in subject ascertainment between studies could produce result 
heterogeneity, and such heterogeneity may be due to true differences in the relevance of 
genetic variants across subgroups or due to bias induced by selection processes. Many 
GWAS statistical models include few covariates, so subgroup effect heterogeneity is not 
explored and there is little hope of correcting selection bias. If gene-environment 
interactions exist, or if the genetic effect occurs only in a subgroup of people, success of the 
GWAS framework may be especially dependent on the sample selection process as it affects 
the distributions of potentially important subject characteristics. More troubling, if genetic 
variants and symptoms of incipient AD interact in determining chances of participating in 
genetic studies, the observed association between the genetic variant and AD may be 
severely biased when estimated in the participants. Indeed, such a process can create an 
observed association that does not match the true effect even among study participants. Of 
course, most studies cannot evaluate this possibility because they have no information on 
study non-participants. Not accounting for these scenarios can result in bias and/or diluted 
statistical power [2–6].
We recently published findings from a prospective cohort with a two-stage sample design 
indicating that genetic associations with LOAD for the APOE locus may differ for 
individuals who attend in-person clinic visits than for the larger community-dwelling 
population, which includes some people who do not attend study visits in a research 
clinic[7]. We determined that risk factor associations with LOAD differed for participants 
who had only in-clinic visits versus the full sample that also included people seen at home. 
For APOE ε4 the estimated hazard ratio for incident LOAD in the full sample was 1.66 
(95% confidence interval [CI] 1.37, 2.01), while in the clinic only dataset, APOE ε4 had a 
hazard ratio of 2.28 (95% CI 1.57, 3.30). The p-value for this difference was 0.008. APOE 
was the only genetic factor we evaluated.
1Abbreviations: ACT: Adult Changes in Thought. AD: Alzheimer’s disease. CI: Confidence interval. HR: Hazard ratio. LOAD: Late-
onset AD.
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The notion that study design could be important in the relevance and magnitude of 
associations with APOE has been known previously[8]. Indeed, while APOE genotype may 
be strongly predictive of LOAD status in specialty clinic settings, this association is 
attenuated in community-based settings[9]. We hypothesized that this pattern could be 
explained by selection bias due to specialty clinic studies lacking home study visit capacity. 
This phenomenon may also apply to other genetic variants. It is important to distinguish 
between the consequences of bias (e.g., estimated effects that are not, on average, centered 
about the true value and diminished power (i.e., less chance of discovering a true effect).
We used genetic and research study data from the Adult Changes in Thought (ACT) study to 
determine whether home study visit capacity would have an influence on the strengths of 
association with LOAD found in ACT with LOAD SNVs from the largest LOAD GWAS 
meta-analysis to date[10].
2. Methods
2.1. Parent study description, ethical considerations, and funding
Methods for ACT have been published[11–13]. The original cohort enrolled 1994–1996 
included 2,581 randomly selected dementia-free people age ≥65 who were members of 
Group Health, a Washington State health care system. An additional 811 participants were 
enrolled 2000–2003, and in 2005 we began continuous enrollment. Participants are 
evaluated at 2-year intervals at a research clinic or in their home at the participant’s choice. 
Other than location (i.e., home vs. clinic), screening research study visits are identical.
Study procedures were approved by Institutional Review Boards of Group Health and the 
University of Washington. Participants provided written informed consent. ACT is supported 
by the National Institute on Aging, which had no role in study design; in the collection, 
analysis, and interpretation of data; in the writing of the report; or in the decision to submit 
the paper for publication.
2.2. LOAD identification
Participants were assessed at home or in clinic every 2 years with the Cognitive Abilities 
Screening Instrument (CASI), for which scores range from 0 to 100 and higher scores 
indicate better cognitive functioning[14]. Participants with scores of 85 or less underwent 
further evaluations, including a clinical examination and a battery of neuropsychological 
tests; dementia evaluations are in the participant’s home regardless of the location of the 
triggering/screening visit. Results of these evaluations, laboratory testing, and imaging 
records were reviewed in a consensus conference, where research criteria were used to 
identify cases of dementia[15] and probable or possible AD[16]. Dementia-free participants 
continued with scheduled follow-up visits. In this study, we are examining whether 
associations between genetic variants and LOAD differ for people who participated in 
biennial screening visits in the clinic compared to all study participants; by design in ACT, 
the dementia evaluations all occur in the participant’s home, so the location of these 
evaluations is not under study here.
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2.3. Genotyping
ACT participants were genotyped in two waves. The bulk of the cohort was genotyped using 
the Illumina Human 660 Quad chip, and a subsequent genotyping wave used the Illumina 
OmniExpress chip. Data from European Americans from both samples were imputed to the 
same CEU Human HapMap reference panels as used in the International Genomics of 
Alzheimer’s Project (IGAP) paper from Lambert et al[10]. APOE genotype was obtained 
separately using standard procedures. Of the other 21 SNVs identified as the top hits in 
Lambert et al.[10], 20 were available in the ACT data either being directly genotyped or 
successfully imputed; the lone exception was the DSG2 SNV.
2.4. Statistical analyses
We limited our analyses to European Americans based on principal components analysis (a 
conventional statistical genetics approach to discern ancestry from GWAS data[17]) as well 
as self-reported white race. We constructed two datasets from the subset of the ACT study 
with at least one follow-up visit and full genotype data (~1/3 of ACT participants): a 
complete data set including information for all participants and all visits (the “all visits” 
dataset), and a second set that mirrored what a clinic based study would have achieved by 
excluding people who never attended a clinic visit (the “clinic only” dataset). By definition, 
participants whose entire set of visits consisted of home visits are not included in the “clinic 
only” dataset. The “all visits” dataset comprises 1697 individuals with a total of 7997 
follow-up visits, 15,972 person-years of time in the ACT study, and 419 cases of incident 
dementia or LOAD resulting in an incidence rate of 26.2 cases per person-year. The “clinic 
only” dataset includes 1308 individuals with a total of 5106 follow-up visits, 10,350 person-
years, and 96 cases of incident dementia or LOAD corresponding to an incidence rate of 9.3 
cases per person-year.
We modeled probable or possible AD as the dependent outcome[16]. Because the ACT 
study is a prospective cohort study and all cases were incident cases of LOAD, we used Cox 
proportional hazards regression models with age as the time axis[18] and included age at 
baseline, sex, and three principal components as covariates. For our primary analyses, we 
also included years of formal schooling as well as self-reports from baseline of diabetes, 
hypertension, coronary heart disease (a composite including self-reported heart attacks, 
angina, coronary artery bypass grafting, or angioplasty), cerebrovascular disease (a 
composite including stroke, transient ischemic attack, or carotid surgery), and quartiles of 
medical comorbidity as estimated with the prescription-medications-based RxRisk 
measure[19]. The assumption of proportional hazards was tenable for all models. We also 
evaluated logistic regression models including only sex, age at baseline, and three principal 
components to facilitate a more direct comparison with the Lambert et al. analyses[10]. Our 
primary analyses with multiple covariates are analogous to epidemiological investigation of 
candidate risk factors, while our sensitivity analyses are analogous to standard genome-wide 
discovery analyses in GWASs.
We compared hazard ratios from the “all visits” and “clinic only” datasets using a 
bootstrapping procedure to evaluate whether differences were plausibly due to sampling 
variability (i.e., chance). We drew (with replacement) random subsets from the “all visits” 
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dataset that were the same size as the “clinic only” dataset. Each randomly drawn resample 
has the same size as the “clinic only” dataset, allowing us to evaluate how often, if the 
“clinic only” dataset was a random sample of the full data set, we would see associations as 
extreme or more than we observed in the actual “clinic only” dataset. In each resampled 
“clinic only” dataset, we performed the same adjusted analyses of the association between 
the SNV and LOAD risk. We determined the proportion of resampled “clinic only” datasets 
with hazard ratios more extreme than those from the actual “clinic only” dataset. The 
bootstrap p-values indicate the proportion of drawn datasets with more extreme findings than 
the actual “clinic only” dataset, which help us understand whether “clinic only” and “all 
visits” hazard ratios differ more than expected by chance alone. We compared the absolute 
values of effect sizes in the actual “clinic only” data set to the resampled datasets so we have 
a 2-sided p-value. The bootstrapped p-values represent the evidence of incompatibility with 
the given statistical model that includes the assumption that the “clinic only” dataset is a 
random sample from the “all visits” dataset. Thus, they provide a test of whether the 
differences between the HRs estimated in the “clinic only” and “all visits” datasets could 
plausibly be due to chance. We consider both nominal (p<0.05) and Bonferroni corrected 
(p<0.05/21) thresholds.
We used Stata 14.1 (StataCorp, College Station, TX) for all analyses.
3. Results
Demographic and clinical data from the LOAD cases and controls are shown in Tables 1 and 
2. These data comprise the “all visits” dataset. There were many distinct patterns of home 
and clinic visits over time for ACT participants. The distribution of pattern types is 
presented in Table 2. For the “clinic only” dataset, we excluded all home visit data. This 
means the 163 people with no clinic visits were excluded. In addition, 389 participants with 
fewer than two clinic visits were excluded because they had no clinic follow-up to contribute 
to survival time. In addition, we excluded the home visits (but kept the clinic visits) for 913 
participants with a mix of home and clinic visits, usually resulting in shorter follow-up time 
and sometimes missing a dementia diagnosis triggered by a home visit for those study 
participants. Minor allele frequencies for variants in genes other than APOE are in 
Supplementary Table 1.
In the “all visits” dataset, we observed significant associations with LOAD hazard for SNVs 
in CR1 (rs6656401, p=0.007), CD2AP (rs10948363, p=0.006), PTK2B (rs28834970, 
p=0.009), CD33 (rs3865444, p=0.026), ABCA7 (rs4147929, p=0.023), and APOE 
(p<0.0001) (see Table 3). Hazard ratios quantify different measures of risk than odds ratios. 
Nevertheless, the corresponding HR estimates are of similar magnitude and in the same 
direction as the OR estimates from Lambert et al.[10] (Table 3 and Supplementary Table). 
For only two of these loci – CR1 and APOE – were results significant in the “clinic only” 
dataset (both p-values <0.0001); no other loci had significant associations with LOAD 
hazard for the “clinic only” sample.
We next evaluated whether differences in estimates from the “clinic only” dataset and the 
“all visits” dataset were larger than expected by chance alone. Four of the 21 investigated 
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SNVs had nominally significant bootstrap p-values; the difference between the HR in the 
clinic only data set and the HR in the all visit data set was unlikely to have emerged by 
chance due to sampling variability. In decreasing order of significance, we observed 
nominally significant results for APOE (p<0.0001), CR1 (rs6656401, p=0.0001), CD33 
(rs3865444, p=0.007), and EPHA1 (rs11771145, p=0.014). Three of these – APOE, CR1, 
and CD33 – were associated with significant LOAD hazard in the “all visits” dataset. When 
employing logistic regression to calculate effect estimates, odds ratios differed significantly 
between the clinic only and all visit data sets for these same three variants, plus the 
PICALM SNV (rs10792832, p=0.014) (Supplementary Table 2). After Bonferroni 
adjustment for testing each of 21 SNVs, the results from APOE and CR1 remained 
significant.
The APOE ε4 allele was associated with higher risk of LOAD, with hazard ratio (HR) for 
the “all visits” dataset of 1.92 (95% CI 1.60, 2.32). As in our previous publication, the 
strength of this association was much higher for the “clinic only” dataset, with a HR of 3.26 
(95% CI 2.30, 4.63). These estimates were more divergent than likely to occur by chance 
alone (bootstrapping p<0.0001). Similar to APOE, results for CR1 on chromosome 1 
(rs6656401) were much stronger in the “clinic only” dataset, with HR 2.13 (95% CI 1.49, 
3.05), than the “all visits” dataset (HR 1.29, 95% CI 1.07, 1.55). Bootstrapping again 
confirmed that these estimates were much more distinct than expected by chance alone 
(bootstrapping p=0.0001; Figure 1).
Results for CD33 on chromosome 19 (rs3865444) from the “all visits” dataset (HR 0.84, 
95% CI 0.71, 0.98) were similar to those observed in Lambert et al. (odds ratio=0.94, 95% 
CI 0.91, 0.96)[10]. Results for the “clinic only” dataset were in the opposite direction 
(HR=1.12, 95% CI 0.81, 1.55), though the confidence interval was broad. Bootstrapping 
results for rs3865444 were nominally significant (bootstrapping p = 0.007). Results for 
rs11771145 associated with EPHA1 on chromosome 7 were essentially null for the “all 
visits” dataset (HR=1.02), and the confidence interval included the odds ratio estimate from 
Lambert et al. (OR = 0.90 95% CI 0.88, 1.18[10]). The result for the “clinic only” dataset 
(HR=0.83) was stronger than that seen in Lambert et al., though the confidence interval was 
wide and included both the point estimate from the “all visits” dataset and that reported by 
Lambert et al. (OR = 0.90 95% CI 0.62, 1.13). Bootstrapping results for rs11771145 
suggested this difference was nominally significant (bootstrap p = 0.014).
For all loci, results from models that included adjustment only for age, sex, and three 
principal components were similar (not shown).
4. Discussion
The ACT study enables each participant to choose whether they would like to have each 
study visit at a central research clinic or at their own home. As participants age, higher 
proportions of participants opt for home study visits[7]. In particular, as many participants 
progress to dementia, their ability or willingness to navigate the world to attend a research 
clinic visit is dramatically attenuated, as indicated by the fact that of the 419 people with 
incident LOAD in this report, only 96 had their AD diagnosed following an in-clinic study 
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screening visit; the remaining 319 people (76%) had their LOAD diagnosed following an in-
home study screening visit. By design, all detailed dementia diagnosis evaluations occur at 
participant homes; we focused here on the location of the screening visits that were either in 
our research clinic or in the participant home. Because the ACT study includes capacity for 
home study screening visits, we are able to address the question of whether associations 
from all ACT study screening visits are different from associations observed among the 
subset of study screening visits at our research clinic. We previously demonstrated large 
differences for risk factors for LOAD and for associations between neuropathology findings 
at autopsy and dementia status during life[7].
Here we performed similar analyses but considered associations with SNVs previously 
found to be associated with LOAD risk[10]. The “clinic only” dataset was smaller than the 
all-visit cohort in terms of the number of people (n=1308 vs. n=1697), follow-up time 
(around 10,000 person-years vs. nearly 16,000 person-years), and number of incident LOAD 
cases (96 vs. 419). It was thus not a surprise that more loci were nominally statistically 
significantly associated with LOAD risk in the “all visits” dataset. As in our previous 
publication, we found large differences between the “clinic only” dataset and the “all visits” 
dataset for APOE genotype. APOE ε4 alleles were associated with increased risk for LOAD 
in the “all visits” dataset, with a HR of 1.92, but they were much more strongly associated in 
the “clinic only” dataset, with a HR of 3.26. We used bootstrapping to determine the 
statistical significance of this difference, and found this difference in risk estimates to be 
very unlikely to be due to chance alone (bootstrapping p<0.0001). This provides strong 
evidence against chance being responsible for differences, which leads to a conclusion that 
the assumptions underlying the model (e.g., no selection bias and no confounding) likely do 
not hold. We similarly found large differences for rs6656401 associated with CR1, where the 
HR estimate was much smaller for the “all visits” dataset (1.29) than the “clinic only” 
dataset (2.13) (bootstrapping p <0.0001). We found a smaller difference for rs3865444 
associated with CD33, however the estimates were in opposite directions, such that the “all 
visits” estimate was consistent with the previously published association from Lambert et al. 
(“all visits” HR=0.84; “clinic only” HR=1.12; bootstrapping p = 0.007).
Thus, with “clinic only” data, we know that the results may be different than what we would 
observe with a more complete dataset that more closely resembles the underlying 
population, but we do not know in which direction to expect any differences. Taken together 
with our prior investigations[7] and viewed as a missing data problem, these results provide 
further evidence that data missing due to the lack of home study visit capacity are missing 
not at random (MNAR). This conclusion has important implications. Results from studies 
with outcomes that are MNAR may be biased – they provide the wrong answer – and we do 
not know the direction of the possible bias. It is not difficult to envision a scenario such that 
the act of opting for a home visit relays important information regarding LOAD risk and the 
subsequent statistical models needed to estimate causal effects.
When data are MNAR, deriving unbiased effect estimates relies on incorporating corrections 
for the missingness mechanism (i.e., what causes people to select out of clinic-based 
studies). Since the missingness mechanism is almost never known, this relies on sensitivity 
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analyses exploring a range of possible missingness mechanisms [20]. Our results can help 
guide such sensitivity analyses in data sets that include only clinic-based data.
We chose to focus only on SNVs previously identified to be associated with LOAD risk. 
Most of these SNVs have been replicated in multiple waves of sampling, though rs3865444 
associated with CD33 was essentially null in the second stage of the Lambert et al. 
study[10]. Since the Lambert et al. paper includes data from many studies with many study 
designs, some of which include and others of which do not include home study visit 
capacity, there may well be additional SNVs that would be discovered if all of the data were 
from studies that include home visit capacity, but that are not identified with genome-wide 
significance levels at present. There is additional expense associated with following older 
study participants at home. Our results strongly support the value of this expenditure in 
terms of the validity of genetic findings.
A similar point can be made in a much broader context outside of home visit capacity and 
even Alzheimer’s disease research. That is, there are study design factors that may appear so 
subtle as to not warrant mention in analysis manuscripts, but that can nevertheless affect 
interpretation and both internal and external validity of results. Finding and addressing these 
areas of heterogeneity could lead to discovery of novel disease variants. Heid et al.[1] 
conducted meta analyses for a SNV found to correlate with BMI and concluded that 
association estimates depended on the design; specifically, whether subjects were recruited 
from a general population or a healthy population. In the case of AD, our investigations 
strongly suggest that whether studies have home study visit capacity can likewise have a 
critical impact on genetic findings of associations with LOAD risk. We suspect there may be 
other apparently subtle design factors that may lead to important heterogeneity across 
studies and that may interfere with our ability to identify associations with LOAD. We could 
speculate that there may be important differences between people who opt for in-home visits 
and people willing to attend a research clinic visit, and that these differences may be related 
to genetic factors and predisposition to LOAD. This is consistent with the results that some 
SNV effects appear more extreme in the “clinic only” sample due to the induced bias while 
others are only significant when using all data possibly solely due to increased sample size. 
An important question is whether the effect estimates in the clinic only sample are correct 
for those individuals, or biased even for that subsample. In other words, are the differences 
we observe due to true effect heterogeneity or due to a bias from the selection process? 
Either explanation is consistent with our statistical findings.
Our findings should be considered in the context of limitations. There is some attrition in the 
ACT study despite including capacity for home visits. Our completeness of follow-up 
index[21] is exemplary but not perfect. It is not known whether similar healthy participant 
bias may influence the results that we observe. We doubt that would be the case due to the 
overall low rates of study attrition, but cannot rule out that possibility. Unmeasured and 
residual confounding are always possibilities in observational studies, though our findings 
were essentially the same with sparser “genetic style” analyses as with covariate-rich 
“epidemiology style” analyses. Underrepresented ethnic diversity of the ACT study is 
somewhat restricted, though the demographic makeup of our study cohort reflects that of 
King County. As in the Lambert et al. paper the analyses presented here were limited to 
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people of European ancestry. Home visit capacity has been specifically advocated as a 
means of increasing underrepresented ethnic participation in dementia studies[22].
Our findings support the importance of home visit data collection capacity in the design of 
genetic studies of LOAD risk. Studies that only include research clinic study visit data 
collection may lead to biased conclusions. These results suggest that new LOAD genetics 
studies at the design stage should consider incorporating home visit data collection capacity 
despite its expense and administrative complexity. Existing studies should routinely report 
on this important detail of study design in reports of study findings. Studies that lack home 
study visit capacity should specify that as a possible limitation, and should be cautious in 
interpreting study findings. Similarly, meta-analyses of LOAD genetic analyses should 
consider whether home study visit capacity may be a source of between-study heterogeneity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context (149 words)
Systematic review
Relevant literature was reviewed using Google Scholar and PubMed. Publications that 
address possible bias in genetic association studies and studies without home visit 
capacity were cited. None address the validity of genome-wide association study results 
in the context of home visit capacity.
Interpretation
Our results suggest that the capacity for home research study visits is an important factor 
in the design of genetic studies of Alzheimer’s disease and dementia. This observation 
implies that there are likely important design differences in genetic studies across 
research areas. When studies are aggregated via meta analysis or otherwise, any inference 
must be carefully interpreted.
Future directions
This paper indicates that home research visit capacity should be considered at the design 
stage of genetic association studies. Other genetic studies of Alzheimer’s disease, 
dementia and other disorders can result in bias due to study design differences when 
aggregating information across potentially disparate cohorts.
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Figure 1. 
Empirical distribution of the beta coefficient for the association between rs6656401 and risk 
of Alzheimer’s disease. We sampled with replacement from the “all visits” data set a sample 
of people the same size as the “clinic only” data set and performed Cox regression on that 
data set of the association between the risk factor and risk of Alzheimer’s disease. We 
captured the beta coefficients from those models; exponentiated beta coefficients from these 
models are hazard ratios. We repeated this procedure 10,000 times. The vertical line at 0.26 
was the result we obtained with the entire “all visits” data set; this value is the natural 
logarithm of the estimated hazard ratio (1.29). The vertical line at 0.70 was the result we 
obtained with the “clinic only” data set; that value is the natural logarithm of the estimated 
hazard ratio (2.01). The graph shows that the bootstrapping results are normally distributed 
with a central tendency very close to the observed value from the entire “all visits” data set; 
the observed result from the “clinic only” data set is far from that value, and none of the 
10,000 sampled data sets had values that extreme. These 10,000 beta coefficients were used 
to arrive at the p-value of 0.0001 shown in Table 3
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Table 1
Demographic and clinical characteristics (n=1697).
Characteristic N or mean % or SD
Male sex 719 42 %
Age 74.9 6.3
Education
 ≤12 years 533 31%
 13–16 years 740 44%
 ≥17 years 424 25%
Diabetes at baseline 139 8%
Hypertension at baseline 642 38%
Heart disease at baseline 305 18%
Cerebrovascular disease at baseline 154 9%
* RxRisk score at baseline
 First quartile 612 36%
 Second quartile 362 21%
 Third quartile 396 23%
 Fourth quartile 322 19%
APOE genotype
 2/2 8 <1%
 2/3 210 12%
 2/4 31 2%
 3/3 1039 62%
 3/4 373 22%
 4/4 24 1%
Number of visits completed
 2 170 10%
 3 239 14%
 4 223 13%
 5 279 16%
 6 169 10%
 7 227 13%
 8–11 390 23%
Total visits 5.7 2.6
Home visits 1.7 1.9
Study cohort
 Original (1994–1996) 1134 67%
 Expansion (2000–2003) 379 22%
 Continuous (2005-) 184 11%
*
Higher RxRisk scores represent greater comorbidity[19]
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Table 2
Distribution of visit patterns
Pattern N (%)
All visits occurred at the clinic 621 (37%)
One or more clinic visits followed by one or more home visits 845 (50%)
One or more clinic visits followed by one or more home visits and at least one more clinic visit 34 (2%)
One or more home visits followed by one or more clinic visits 11 (1%)
One or more home visits followed by one or more of clinic visits and at least one more home visit 23 (1%)
All visits occurred at home 163 (10%)
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